表紙
市場調査レポート

Summit Corporation plc:製品パイプライン分析

Summit Corporation plc - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 204929
出版日 ページ情報 英文 46 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
Summit Corporation plc:製品パイプライン分析 Summit Corporation plc - Product Pipeline Review - 2015
出版日: 2015年02月28日 ページ情報: 英文 46 Pages
概要

当レポートでは、Summit Corporation plcにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Summit Corporation plcの基本情報

Summit Corporation plcの概要

  • 主要情報
  • 企業情報

Summit Corporation plc:R&Dの概要

  • 主な治療範囲

Summit Corporation plc:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Summit Corporation plc:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第II相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

Summit Corporation plc:薬剤プロファイル

  • SMT-19969
  • SMTC-1100
  • Seglin O-linked N-acetylglucosaminidase Inhibitors
  • SMT-14224
  • SMT-15000
  • SMT-21829
  • SMTC-2100
  • Next Generation Utrophin Modulator、など

Summit Corporation plc:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Summit Corporation plc:最近のパイプライン動向

Summit Corporation plc:休止中のプロジェクト

Summit Corporation plc:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
  • SMTD-001

Summit Corporation plc:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC06833CDB

Summary

Global Markets Direct's, 'Summit Corporation plc - Product Pipeline Review - 2015', provides an overview of the Summit Corporation plc's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Summit Corporation plc's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Summit Corporation plc including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Summit Corporation plc's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Summit Corporation plc's pipeline products

Reasons to buy

  • Evaluate Summit Corporation plc's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Summit Corporation plc in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Summit Corporation plc's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Summit Corporation plc and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Summit Corporation plc
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Summit Corporation plc and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Summit Corporation plc Snapshot
    • Summit Corporation plc Overview
    • Key Information
    • Key Facts
  • Summit Corporation plc - Research and Development Overview
    • Key Therapeutic Areas
  • Summit Corporation plc - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Summit Corporation plc - Pipeline Products Glance
    • Summit Corporation plc - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Summit Corporation plc - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • Summit Corporation plc - Drug Profiles
    • SMT-19969
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SMTC-1100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NSI-189
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit O-linked N-acetylglucosaminidase for Neurodegenerative Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Activate Utrophin for Duchenne Muscular Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Target Utrophin for Duchenne Muscular Dystrophy
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SMT-14224
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SMT-15000
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SMT-21829
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • SMTC-2100
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit NS3 Helicase for Hepatitis C
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Summit Corporation plc - Pipeline Analysis
    • Summit Corporation plc - Pipeline Products by Target
    • Summit Corporation plc - Pipeline Products by Route of Administration
    • Summit Corporation plc - Pipeline Products by Molecule Type
    • Summit Corporation plc - Pipeline Products by Mechanism of Action
  • Summit Corporation plc - Recent Pipeline Updates
  • Summit Corporation plc - Dormant Projects
  • Summit Corporation plc - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • SMTD-001
  • Summit Corporation plc - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Summit Corporation plc, Key Information
  • Summit Corporation plc, Key Facts
  • Summit Corporation plc - Pipeline by Indication, 2015
  • Summit Corporation plc - Pipeline by Stage of Development, 2015
  • Summit Corporation plc - Monotherapy Products in Pipeline, 2015
  • Summit Corporation plc - Partnered Products in Pipeline, 2015
  • Summit Corporation plc - Partnered Products/ Combination Treatment Modalities, 2015
  • Summit Corporation plc - Out-Licensed Products in Pipeline, 2015
  • Summit Corporation plc - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Summit Corporation plc - Phase II, 2015
  • Summit Corporation plc - Phase I, 2015
  • Summit Corporation plc - Preclinical, 2015
  • Summit Corporation plc - Discovery, 2015
  • Summit Corporation plc - Pipeline by Target, 2015
  • Summit Corporation plc - Pipeline by Route of Administration, 2015
  • Summit Corporation plc - Pipeline by Molecule Type, 2015
  • Summit Corporation plc - Pipeline Products by Mechanism of Action, 2015
  • Summit Corporation plc - Recent Pipeline Updates, 2015
  • Summit Corporation plc - Dormant Developmental Projects,2015
  • Summit Corporation plc - Discontinued Pipeline Products, 2015
  • Summit Corporation plc, Subsidiaries

List of Figures

  • Summit Corporation plc - Pipeline by Top 10 Indication, 2015
  • Summit Corporation plc - Pipeline by Stage of Development, 2015
  • Summit Corporation plc - Monotherapy Products in Pipeline, 2015
  • Summit Corporation plc - Partnered Products in Pipeline, 2015
  • Summit Corporation plc - Pipeline by Top 10 Target, 2015
  • Summit Corporation plc - Pipeline by Top 10 Route of Administration, 2015
  • Summit Corporation plc - Pipeline by Top 10 Molecule Type, 2015
  • Summit Corporation plc - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top